Regulation of neurotensin receptor function by the arachidonic acid-lipoxygenase pathway in prostate cancer PC3 cells

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 74, Issue 2, 2006, Pages 93-107

  Carraway, Robert E ^a   Hassan, Sazzad ^a   Cochrane, David E ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 2 MORPHOLINO 8 PHENYLCHROMONE; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 5,8,11,14 ICOSATETRAYNOIC ACID; 9 (TETRAHYDRO 2 FURYL)ADENINE; ALPHA PENTYL 3 (2 QUINOLYLMETHOXY)BENZYL ALCOHOL; ARACHIDONATE LIPOXYGENASE; ARACHIDONIC ACID; BAICALEIN; BETA 2 ADRENERGIC RECEPTOR; BOMBESIN RECEPTOR; DOCEBENONE; EPIDERMAL GROWTH FACTOR RECEPTOR; GOSSYPOL; INDOMETACIN; INOSITOL PHOSPHATE; IODINE 125; LIPOXYGENASE INHIBITOR; NEUROTENSIN; NEUROTENSIN RECEPTOR; NORDIHYDROGUAIARETIC ACID; PHOSPHOLIPASE A2 INHIBITOR; PROSTAGLANDIN SYNTHASE INHIBITOR; RETINOIC ACID; TOMELUKAST; UNINDEXED DRUG; VASOPRESSIN V1 RECEPTOR;

ARACHIDONIC ACID METABOLISM; ARTICLE; CANCER CELL CULTURE; CELL SPECIFICITY; CELL TRANSPORT; CONTROLLED STUDY; DRUG EFFECT; DRUG SPECIFICITY; HUMAN; HUMAN CELL; IC 50; LIPID PEROXIDATION; MEMBRANE BINDING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; RECEPTOR AFFINITY; SIGNAL TRANSDUCTION;

ARACHIDONATE LIPOXYGENASES; BINDING, COMPETITIVE; CELL LINE, TUMOR; FEEDBACK, BIOCHEMICAL; HUMANS; HYDROGEN PEROXIDE; INOSITOL PHOSPHATES; LIPOXYGENASE INHIBITORS; MALE; NEUROTENSIN; OXIDANTS; PROSTATIC NEOPLASMS; PROTEIN BINDING; REACTIVE OXYGEN SPECIES; RECEPTORS, NEUROTENSIN; SIGNAL TRANSDUCTION; UP-REGULATION;

ANIMALIA;

EID: 30544446063     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2005.11.005     Document Type: Article

References (53)

1. R.E. Carraway, and S.E. Leeman Characterization of radioimmunoassayable neurotensin in the rat. Its differential distribution in the central nervous system, small intestine, and stomach J. Biol. Chem. 251 1976 7045 7052
2. L. Seethalakshmi, S.P. Mitra, P.R. Dobner, M. Menon, and R.E. Carraway Neurotensin receptor expression in prostate cancer cell line and growth effect of NT at physiological concentrations Prostate 31 1997 183 192
3. 2+ channel blockers enhance neurotensin (NT) binding and inhibit NT-induced inositol phosphate formation in prostate cancer PC3 cells J. Pharmacol. Exp. Ther. 307 2003 640 650
4. 2+ stores depletion, is mediated by arachidonic acid Cell Calcium 24 1998 293 304
5. J.D. Clark, L.L. Lin, R.W. Kriz, C.S. Ramesha, L.A. Sultzman, A.Y. Lin, N. Milona, and J.L. Knopf A novel arachidonic acid-selective cytosolic PLA2 contains a Ca(2+)-dependent translocation domain with homology to PKC and GAP Cell 65 1991 1043 1051
6. R.A. Nemenoff, S. Winitz, N.X. Qian, V. Van Putten, G.L. Johnson, and L.E. Heasley Phosphorylation and activation of a high molecular weight form of phospholipase A2 by p42 microtubule-associated protein 2 kinase and protein kinase C J. Biol. Chem. 268 1993 1960 1964
7. A.W. Ford-Hutchinson, M. Gresser, and R.N. Young 5-Lipoxygenase Annu. Rev. Biochem. 63 1994 383 417
8. R.E. Carraway, D.E. Cochrane, R. Salmonsen, K. Muraki, and W. Boucher Neurotensin elevates hematocrit and plasma levels of the leukotrienes, LTB4, LTC4, LTD4 and LTE4, in anesthetized rats Peptides 12 1991 1105 1111
9. S. Hassan, and R. Carraway Signaling mechanisms involved in the activation of arachidonic acid metabolism in PC3 cell growth by neurotensin, and its interaction with EGF receptor Neuropeptides 37 2003 184
10. V.E. Steele, C.A. Holmes, E.T. Hawk, L. Kopelovich, R.A. Lubet, J.A. Crowell, C.C. Sigman, and G.J. Kelloff Lipoxygenase inhibitors as potential cancer chemopreventives Cancer Epidemiol. Biomarkers Prev. 8 1999 467 483
11. A.A. Chaudry, K.W. Wahle, S. McClinton, and L.E. Moffat Arachidonic acid metabolism in benign and malignant prostatic tissue in vitro: effects of fatty acids and cyclooxygenase inhibitors Int. J. Cancer 57 1994 176 180
12. K.M. Anderson, J.B. Wygodny, F. Ondrey, and J. Harris Human PC-3 prostate cell line DNA synthesis is suppressed by eicosatetraynoic acid, an in vitro inhibitor of arachidonic acid metabolism Prostate 12 1988 3 12
13. J. Ghosh, and C.E. Myers Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase Biochem. Biophys. Res. Commun. 235 1997 418 423
14. J. Ghosh, and C.E. Myers Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells Proc. Natl. Acad. Sci. USA 95 1998 13182 13187
15. S. Hassan, R.E. Carraway, Involvement of arachidonic acid and EGF receptor in neurotensin-induced prostate cancer PC3 cell growth, Regul. Peptides, 2006, in press.
16. R.E. Carraway, S. Hassan, and D.E. Cochrane Polyphenolic antioxidants mimic the effects of 1,4-dihydropyridines on neurotensin receptor function in PC3 cells J. Pharmacol. Exp. Ther. 309 2004 92 101
17. V.J. Thannickal, and B.L. Fanburg Reactive oxygen species in cell signaling Am. J. Physiol. Lung Cell. Mol. Physiol. 279 2000 L1005 L1028
18. K.R. Stone, D.D. Mickey, H. Wunderli, G.H. Mickey, and D.F. Paulson Isolation of a human prostate carcinoma cell line (DU 145) Int. J. Cancer 21 1978 274 281
19. J.C. Bozou, N. Rochet, I. Magnaldo, J.P. Vincent, and P. Kitabgi Neurotensin stimulates inositol trisphosphate-mediated calcium mobilization but not protein kinase C activation in HT29 cells. Involvement of a G-protein Biochem. J. 264 1989 871 878
20. M. Wu, and S.M. Ho PMP24, a gene identified by MSRF, undergoes DNA hypermethylation-associated gene silencing during cancer progression in an LNCaP model Oncogene 23 2004 250 259
21. K. Jung, H.W. Krell, B. Ortel, T. Hasan, A. Romer, D. Schnorr, S.A. Loening, and M. Lein Plasma matrix metalloproteinase 9 as biomarker of prostate cancer progression in Dunning (Copenhagen) rats Prostate 54 2003 206 211
22. 2 in cultured endothelial cells Arch. Biochem. Biophys. 302 1993 348 355
23. 125I-labeled neurotensin to membranes from porcine brain Peptides 14 1993 185 189
24. C.A. Sutherland, and D. Amin Relative activities of rat and dog platelet phospholipase A2 and diglyceride lipase. Selective inhibition of diglyceride lipase by RHC 80267, J. Biol. Chem. 257 1982 14006 14010
25. J. Ghosh Rapid induction of apoptosis in prostate cancer cells by selenium: reversal by metabolites of arachidonate 5-lipoxygenase Biochem. Biophys. Res. Commun. 315 2004 624 635
26. H. Katsuki, and S. Okuda Arachidonic acid as a neurotoxic and neurotrophic substance Prog. Neurobiol. 46 1995 607 636
27. M. Los, H. Schenk, K. Hexel, P.A. Baeuerle, W. Droge, and K. Schulze-Osthoff IL-2 gene expression and NF-kappa B activation through CD28 requires reactive oxygen production by 5-lipoxygenase EMBO J. 14 1995 3731 3740
28. A. Gugliucci, L. Ranzato, L. Scorrano, R. Colonna, V. Petronilli, C. Cusan, M. Prato, M. Mancini, F. Pagano, and P. Bernardi Mitochondria are direct targets of the lipoxygenase inhibitor MK886. A strategy for cell killing by combined treatment with MK886 and cyclooxygenase inhibitors, J. Biol. Chem. 277 2002 31789 31795
29. J. St-Pierre, J.A. Buckingham, S.J. Roebuck, and M.D. Brand Topology of superoxide production from different sites in the mitochondrial electron transport chain J. Biol. Chem. 277 2002 44784 44790
30. +3/ascorbate-stimulated lipid peroxidation in rat brain slices Gen. Pharmacol. 31 1998 385 391
31. S. Ozgova, J. Hermanek, and I. Gut Different antioxidant effects of polyphenols on lipid peroxidation and hydroxyl radicals in the NADPH-, Fe-ascorbate- and Fe-microsomal systems Biochem. Pharmacol. 66 2003 1127 1137
32. O. Werz, D. Szellas, and D. Steinhilber Reactive oxygen species released from granulocytes stimulate 5-lipoxygenase activity in a B-lymphocytic cell line Eur. J. Biochem. 267 2000 1263 1269
33. G. Lenaz The mitochondrial production of reactive oxygen species: mechanisms and implications in human pathology IUBMB Life 52 2001 159 164
34. K.K. Griendling, D. Sorescu, and M. Ushio-Fukai NAD(P)H oxidase: role in cardiovascular biology and disease Circ. Res. 86 2000 494 501
35. M. Aslan, and T. Ozben Oxidants in receptor tyrosine kinase signal transduction pathways Antioxid. Redox Signal 5 2003 781 788
36. L. Behrend, G. Henderson, and R.M. Zwacka Reactive oxygen species in oncogenic transformation Biochem. Soc. Trans. 31 2003 1441 1444
37. C.A. Rouzer, A.W. Ford-Hutchinson, H.E. Morton, and J.W. Gillard MK886, a potent and specific leukotriene biosynthesis inhibitor blocks and reverses the membrane association of 5-lipoxygenase in ionophore-challenged leukocytes J. Biol. Chem. 265 1990 1436 1442
38. N. Flamand, M.E. Surette, S. Picard, S. Bourgoin, and P. Borgeat Cyclic AMP-mediated inhibition of 5-lipoxygenase translocation and leukotriene biosynthesis in human neutrophils Mol. Pharmacol. 62 2002 250 256
39. 1H-tetrazol-5-yl) butoxy greater than phenyl greater than ethanone, an orally active leukotriene D4 antagonist J. Pharmacol. Exp. Ther. 233 1985 148 157
40. S.P. Mathupala, A. Rempel, and P.L. Pedersen Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase J. Bioenerg. Biomembr. 29 1997 339 343
41. S.V. Ambudkar, C. Kimchi-Sarfaty, Z.E. Sauna, and M.M. Gottesman P-glycoprotein: from genomics to mechanism Oncogene 22 2003 7468 7485
42. C.L. Arteaga, T.T. Ramsey, L.K. Shawver, and C.A. Guyer Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site J. Biol. Chem. 272 1997 23247 23254
43. R.B. Lichtner, A. Menrad, A. Sommer, U. Klar, and M.R. Schneider Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors Cancer Res. 61 2001 5790 5795
44. U. Gether, and B.K. Kobilka G protein-coupled receptors. II. Mechanism of agonist activation J. Biol. Chem. 273 1998 17979 17982
45. S. Martin, V. Navarro, J.P. Vincent, and J. Mazella Neurotensin receptor-1 and -3 complex modulates the cellular signaling of neurotensin in the HT29 cell line Gastroenterology 123 2002 1135 1143
46. C.F. Ferris, R.E. Carraway, R.A. Hammer, and S.E. Leeman Release and degradation of neurotensin during perfusion of rat small intestine with lipid Regul. Peptides 12 1985 101 111
47. S. Rosell, and A. Rokaeus The effect of ingestion of amino acids, glucose and fat on circulating neurotensin-like immunoreactivity (NTLI) in man Acta Physiol. Scand. 107 1979 263 267
48. J.C. Reubi, B. Waser, J.C. Schaer, and J.A. Laissue Neurotensin receptors in human neoplasms: high incidence in Ewing's sarcomas Int. J. Cancer 82 1999 213 218
49. L.N. Kolonel, A.M. Nomura, and R.V. Cooney Dietary fat and prostate cancer: current status J. Natl. Cancer Inst. 91 1999 414 428
50. S. Hassan, P.R. Dobner, and R.E. Carraway Involvement of MAP-kinase, PI3-kinase and EGF-receptor in the stimulatory effect of Neurotensin on DNA synthesis in PC3 cells Regul. Peptides 120 2004 155 166
51. J.L. Walker, J. Loscalzo, and Y.Y. Zhang 5-Lipoxygenase and human pulmonary artery endothelial cell proliferation Am. J. Physiol. Heart Circ. Physiol. 282 2002 H585 H593
52. N. Flamand, S. Boudreault, S. Picard, M. Austin, M.E. Surette, H. Plante, E. Krump, M.J. Vallee, C. Gilbert, P. Naccache, M. Laviolette, and P. Borgeat Adenosine, a potent natural suppressor of arachidonic acid release and leukotriene biosynthesis in human neutrophils Am. J. Respir. Crit. Care Med. 161 2000 S88 S94
53. O.P. Radmark The molecular biology and regulation of 5-lipoxygenase Am. J. Respir. Crit. Care Med. 161 2000 S11 S15